Term ended Apr 12, 2024 · High confidence
20-year base term ended Apr 12, 2024
Held by GRT US Holding, Inc.
Filed Apr 8, 2011 as application 13/083,306 · Granted Sep 11, 2012
Base term, 20 years from filing
Today
Term ended Apr 12, 2024
2004
2026
Clock starts
Apr 12, 2004
Apr 12, 2004
Term ended
Apr 12, 2024
Apr 12, 2024
Granted
Sep 11, 2012
Sep 11, 2012
base term
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,943,166, to Apr 12, 2024. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 12, 2004, when application 10/823,426, the earliest non-provisional in its chain, was filed (this one was filed Apr 8, 2011) | Apr 12, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,943,166) | resolves to Apr 12, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Apr 12, 2024 | High confidence |
This family
| US 7,943,166 | In force Sep 2027 | Sep 2027 |
| US 8,273,390 | Term ended Apr 2024 | Apr 2024 |
| US 8,263,093 | this patent Apr 2024 | Apr 2024 |
| US 8,734,770 | Term ended Apr 2024 | Apr 2024 |
| US 9,750,707 | Term ended Apr 2024 | Apr 2024 |
| US 10,653,647 | Term ended Apr 2024 | Apr 2024 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 22, 2011 Reel 26170, frame 993 | Muhammad, Naweed; Jamieson, Gene C.; Bley, Keith R.; Chanda, Sanjay | Neurogesx, Inc. | Assignment of Assignor's Interest |
| Nov 13, 2012 Reel 29291, frame 807 | Neurogesx, Inc. | Hercules Technology Growth Capital, Inc. | Security Agreement |
| Jul 10, 2013 Reel 30777, frame 782 | Hercules Technology Growth Capital, Inc. | Neurogesx, Inc. | Assignment and Release of Security Interest |
| Dec 12, 2013 Reel 31775, frame 168 | Neurogesx, Inc. | Acorda Therapeutics, Inc. | Assignment of Assignor's Interest |
| Jun 10, 2016 Reel 38950, frame 436 | Acorda Therapeutics, Inc.; Civitas Therapeutics, Inc.; Neuronex, Inc. | JPMorgan Chase Bank, N.A., as Administrative Agent | Security Interest |
| May 31, 2017 reel/frame not recorded | JPMorgan Chase Bank, N.A., as Administrative Agent | Neuronex, Inc. | Release of Security Interest |
| May 31, 2017 reel/frame not recorded | JPMorgan Chase Bank, N.A., as Administrative Agent | Civitas Therapeutics, Inc. | Release of Security Interest |
| May 31, 2017 reel/frame not recorded | JPMorgan Chase Bank, N.A., as Administrative Agent | Acorda Therapeutics, Inc. | Release of Security Interest |
| May 31, 2017 Reel 42643, frame 878 | JPMorgan Chase Bank, N.A., as Administrative Agent | Neuronex, Inc.; Civitas Therapeutics, Inc.; Acorda Therapeutics, Inc. | Release of Security Interest |
| May 22, 2019 Reel 49260, frame 707 | Acorda Therapeutics, Inc. | Grünenthal GmbH | Assignment of Assignor's Interest |
| Aug 15, 2019 Reel 50065, frame 195 | Grünenthal GmbH | GRT US Holding, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,943,166, ends no earlier than this term, so it caps nothing.
Citations
18
later US patents cite this one
That is above the median of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.